Trustees of Princeton University bought a new stake in shares of Myokardia Inc (NASDAQ:MYOK) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 147,408 shares of the biotechnology company’s stock, valued at approximately $6,206,000. Myokardia accounts for 5.7% of Trustees of Princeton University’s investment portfolio, making the stock its 4th biggest position.
Other large investors have also made changes to their positions in the company. SG Americas Securities LLC bought a new stake in Myokardia during the 4th quarter valued at approximately $185,000. Quantbot Technologies LP bought a new stake in Myokardia during the 3rd quarter valued at approximately $202,000. Dimensional Fund Advisors LP bought a new stake in Myokardia during the 3rd quarter valued at approximately $212,000. Teacher Retirement System of Texas bought a new stake in Myokardia during the 4th quarter valued at approximately $298,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Myokardia during the 3rd quarter valued at approximately $355,000. Hedge funds and other institutional investors own 78.38% of the company’s stock.
In other news, insider Anastasios Gianakakos sold 3,000 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $51.05, for a total value of $153,150.00. Following the completion of the transaction, the insider now directly owns 77,390 shares of the company’s stock, valued at approximately $3,950,759.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kevin P. Starr sold 816,326 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $42.00, for a total value of $34,285,692.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 840,326 shares of company stock valued at $35,376,662. Insiders own 33.40% of the company’s stock.
MYOK has been the subject of several recent research reports. BidaskClub raised Myokardia from a “hold” rating to a “buy” rating in a report on Saturday, February 17th. ValuEngine raised Myokardia from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Credit Suisse Group reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Myokardia in a report on Thursday, January 18th. Zacks Investment Research cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, TheStreet cut Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Myokardia presently has an average rating of “Buy” and a consensus target price of $55.67.
COPYRIGHT VIOLATION NOTICE: “Trustees of Princeton University Buys Shares of 147,408 Myokardia Inc (MYOK)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3225975/trustees-of-princeton-university-buys-shares-of-147408-myokardia-inc-myok.html.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myokardia Inc (NASDAQ:MYOK).
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.